¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Rieder's cell leukemia, lymphocyte"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® white blood cell(WBC), leukocyte ÇÑ±Û ¹éÇ÷±¸
¼³¸í   
  Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, È¤Àº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀΠÇö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù.
¿µ¹® mast cell ÇÑ±Û ºñ¸¸ ¼¼Æ÷
¼³¸í   
  µ¿¹°ÀÇ °áÇÕ Á¶Á÷ °¡¿îµ¥ ³Î¸® ºÐÆ÷Çϴ ¼¼Æ÷. °áÇÕÁ¶Á÷°ú Á¡¸·Á¶Á÷ ³»¿¡ Àִ ȣ¿°±â¼º »ö¼Ò·Î ÀÌ¿°»ö¼º(metachromasia)À» ³ªÅ¸³»´Â °ú¸³À» °¡Áø ¹æÃßÇüÀÇ ¼¼Æ÷¿¡ ÀÛÀº µÕ±Ù ÇÙÀ» °¡Áø´Ù. ºñ¸¸¼¼Æ÷ÀǠǥ¸é¿¡´Â IgE¿¡ ´ëÇÑ ¼ö¿ëü°¡ Á¸ÀçÇϸç, ¼ö¿ëü¿¡ °áÇÕÇÑ IgE ºÐÀڵ鳢¸® ´Ù°¡ÀÇ Ç׿ø¿¡ ÀÇÇØ ¼­·Î ¿¬°áµÇ¸é ºñ¸¸¼¼Æ÷ °ú¸³Å»Ãâ ¹ÝÀÀÀÌ ÀϾ, È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ, ÇìÆÄ¸° µîÀÇ È­ÇÐÀü´Þ ¹°ÁúÀÌ ¹æÃâµÇ¾î, Áï½ÃÇü ¾Ë·¹¸£±â ¹ÝÀÀ µîÀÇ Áõ»óÀ» ÀÏÀ¸Å²´Ù. ÇǺÎ, À帷, Ç÷°ü ÁÖÀ§, Á¡¸· ÁÖº¯¿¡ ÀÖ´Ù.
¿µ¹® cell ÇÑ±Û ¼¼Æ÷
¼³¸í   
  »ý¸íü¸¦ ÀÌ·ç´Â ±¸Á¶Àû, ±â´ÉÀû ´ÜÀ§.
  
  ÇÙÀÇ À¯¹«¿¡ µû¶ó¼­ À¯ÇÙ¼¼Æ÷¿Í ¹«ÇÙ¼¼Æ÷·Î ³ª´­ ¼ö°¡ ÀÖ´Ù. ¹«ÇÙ¼¼Æ÷¶õ ÇÙÀÌ ¾ø´Â ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. ÇÙÀ̶õ À¯ÀüÁ¤º¸¸¦ °¡Áö°í Àִ ¿°»öü¸¦ º¸°üÇϴ °÷Àε¥ ¹«ÇÙ¼¼Æ÷¿¡¼­´Â ¿°»öü°¡ ¼¼Æ÷¼Ó¿¡ ±×³É ³ëÃâµÇ¾î ÀÖ´Ù. ´ë°³ ¼¼Æ÷ ÇϳªÇϳª°¡ µ¶¸³µÈ »ý¸íüÀÇ ¿ªÇÒÀ» Çϴ ´Ü¼¼Æ÷»ý¹°·Î¼­ ¿ÜºÎȯ°æÀ¸·ÎºÎÅÍ ÀÚ½ÅÀ» º¸È£ÇÒ ¼ö Àִ °ß°íÇÑ ¼¼Æ÷º®À» °¡Áö°í ÀÖ´Ù. À¯ÇÙ¼¼Æ÷¶õ ÇÙÀ» °¡Áö°í À־ À¯ÀüÁ¤º¸°¡ Àִ ¿°»öü°¡ ¼¼Æ÷ÀÇ ´Ù¸¥ ºÎºÐ°ú ±¸ºÐµÇ¾î ÇÙ¼Ó¿¡ µé¾îÀÖ´Ù. ¼¼Æ÷¼Ó¿¡¼­ ÇÙ¿ÜÀÇ ºÎºÐ(À̸¦ ¼¼Æ÷ÁúÀ̶ó ÇÑ´Ù)¿¡´Â ¿©·¯ °¡Áö ¼¼Æ÷ÀÇ ¼Ò±â°üÀÌ À־ ¼¼Æ÷ÀÇ ´Ù¾çÇÑ ±â´ÉÀ» ºÐ´ãÇÑ´Ù.
  
  ¢ÂÀ¯ÇÙ¼¼Æ÷ÀÇ ±âº» ±¸Á¶
  
  1.¼¼Æ÷¸·-¼¼Æ÷¸¦ µÑ·¯½Î¼­ ÁÖÀ§È¯°æ°ú ºÐ¸®ÇÏ¿© ¼¼Æ÷ÀÇ ³»È¯°æÀ» À¯ÁöÇÑ´Ù.
  
  2.ÇüÁú³»¼¼¸Á(endoplasmic reticulum)-´ÜÀ§¸·À¸·Î µÑ·¯½×¿© Àִ ºÒ±ÔÄ¢ÇÑ ¸Á»ó±¸Á¶ÀÌ´Ù. ÀÌ ¸Á»ó±¸Á¶ÀÇ ³»ºÎ¸¦ ¼Ò°­, ¼ÒÁ¶¶ó°í ºÎ¸¥´Ù. ¿©±â¿¡´Â Ç¥¸éÀÌ ¸Å²öÇÑ ¹«°ú¸³ÇüÁú³»¼¼¸Á°ú Ç¥¸éÀÌ ºÒ±ÔÄ¢ÇÑ °ú¸³ÇüÁú³»¼¼¸ÁÀÇ µÎ °¡Áö°¡ ÀÖ´Ù. °ú¸³ÇüÁú³»¼¼¸ÁÀÇ °æ¿ì´Â Ç¥¸é¿¡ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ ¸®º¸¼ØÀ̶ó´Â °ÍÀÌ ºÎÂøµÇ¾î ÀÖ´Ù. À̰÷Àº ÁַΠ¼¼Æ÷¹ÛÀ¸·Î ºÐºñÇÒ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ Àå¼ÒÀÌ´Ù. ¹«°ú¸³ÇüÁú³»¼¼¸ÁÀº Ç¥¸é¿¡ ¸®º¸¼ØÀÌ ºÎÂøµÇ¾î ÀÖÁö ¾ÊÀº °ÍÀ» ¸»Çϸç, À̰÷¿¡¼­´Â ÁÖ·Î ÇØµ¶ÀÛ¿ë, ±Û¸®ÄÚ°ÕÀÇ ÇÕ¼º, ½ºÅ×·ÎÀ̵åÈ£¸£¸óÀÇ ÇÕ¼º µîÀÌ ÀϾ´Ù.
  
  3.¸®º¸¼Ø-´Ü¹éÁúÀ» ÇÕ¼ºÇϴ ¿ªÇÒÀ» Çϴ °÷ÀÌ´Ù.À̰ÍÀº ¼¼Æ÷Áú¿¡ Á¸ÀçÇϴ ÀÚÀ¯¸®º¸¼Ø°ú °ú¸³ÇüÁú³»¼¼¸Á¿¡ ºÎÂøÀÌ µÇ¾î Á¸ÀçÇϴ ºÎÂø¸®º¸¼ØÀÇ µÎ °¡Áö·Î ³ª´«´Ù. ÀÚÀ¯¸®º¸¼ØÀº ÁַΠ¼¼Æ÷³»¿¡¼­ ÇÊ¿äÇÑ ´Ü¹éÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» Ç졒ʼÎÂø¸®º¸¼ØÀº ¼¼Æ÷¹ÛÀ¸·Î ºÐºñÇÒ ´Ü¹éÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù.
  
  4.°ñÁöÀåÄ¡(Golgi apparatus)-ÇÙÁÖÀ§¿¡ ºÐÆ÷Çϴ ³³ÀÛÇØÁø ÁָӴϸð¾çÀÇ °ÍÀÌ ÁßøµÇ¾î Çü¼ºµÈ ÃþÆÇ ¸ð¾çÀÇ ±¸Á¶¹°·Î °ú¸³ÇüÁú³»¼¼¸Á¿¡¼­ »ý¼ºµÇ¾î ¿ÜºÎ·Î ºÐºñµÉ ´Ü¹éÁúÀ» ¸ð¾Æ¼­ ³óÃà, Æ÷ÀåÇÏ¿© °ú¸³À» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù.
  
  5.»ç¸³Ã¼(mitochondria)-±¸Çü, ³­ÇüÀÇ ±ä ¸·´ë±â ¸ð¾çÀ¸·Î Å©±â°¡ ´Ù¾çÇÑ ±¸Á¶¹°. »ý¹°Ã¼ÀÇ ¿¡³ÊÁö ÀúÀå¹°ÁúÀΠATP¸¦ »ý»êÇϴ ¿ªÇÒÀ» ÇÑ´Ù. ¶Ç ¼¼Æ÷¿Í ´Ù¸¥ ÀڽŸ¸ÀÇ À¯ÀüÁ¤º¸¸¦ °¡Áø DNA, RNA¸¦ °¡Áö°í ÀÖ´Ù. ¸ð¾ç, Å©±â°¡ ¼¼±Õ°ú ºñ½ÁÇϸç ÀÚüÁõ½Ä¼º µî µ¶¸³µÈ »ý¸íü·Î¼­ ÇÊ¿äÇÑ ¿ä°ÇÀ» °®Ãß°í À־ ¼¼Æ÷¿Í °ø»ý°ü°è¸¦ °¡Áø µ¶¸³µÈ ¼¼Æ÷·Î »ý°¢Çϰí ÀÖ´Ù.
  
  6.¿ëÇØ¼Òü(lysosome)-ÀÛÀº ±¸ÇüÀÇ ¼Òü·Î ¿©·¯ °¡Áö ºÐÇØÈ¿¼Ò¸¦ °¡Áø´Ù. ¼¼Æ÷¿Ü°è¿¡¼­ µé¾î¿Â ¹°Áú°ú °áÇÕÇÏ¿© ±× ¹°ÁúµéÀ» ¿ëÇØÇϴ ¿ªÇÒÀ» Çϰí, ¿À·¡µÈ ¼¼Æ÷¼Ò±â°üµéÀ» Á¦°ÅÇϴ ¿ªÇÒµµ ÇÑ´Ù.
  
  7.¼¼Æ÷ÇÙ(nucleus)-±¸Çü, ³­ÇüÀ¸·Î ¼¼Æ÷ÀÇ Á߽ɿ¡ À§Ä¡ÇÑ´Ù. ÇÙ³»¿¡´Â À¯ÀüÁ¤º¸°¡ Àִ ¹°ÁúÀΠ¿°»öü°¡ Á¸ÀçÇÑ´Ù.
  
  8.Á߽ɼÒü(centrosome)-ÇÙÁÖÀ§¿¡ Á¸ÀçÇϸ鼭 ÇÙÀÇ ºÐ¿­½Ã¿¡ ¾çÂÊÀÇ ¿°»öü¸¦ ´ç±â´Â ÀÛÀº ¼¶À¯¸¦ ¸¸µå´Â ¿ªÇÒÀ» Çϴ °÷.
  
  ¼¼Æ÷
¿µ¹® cell-mediated immunity ÇÑ±Û ¼¼Æ÷¸Å°³¸é¿ª
¼³¸í   
  ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£Çϴ ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â Æ¯ÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù.
  
  ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº Æ¯Á¤ÇÑ ¹°Áú¿¡ °ü°èÇϴ ¸é¿ªÀÌ ¾Æ´Ï¶ó Æ¯Á¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö Àִ ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀΠ°Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼­ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇϴ ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀǠȰµ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ Æ¯ÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö Àִ ¼¼Æ÷¸¦ »ý¼ºÇϰԠÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇϰԠÇϴ °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® nerve cell ÇÑ±Û ½Å°æ¼¼Æ÷
¼³¸í   
  ½Å°æ¼¼Æ÷´Â ¿Ã¹Ù¸¥ ½Å°æÀü´ÞÀ» À§ÇÑ °¢ ºÎºÐº°·Î ³ª´µ¾îÁ® ÀÖ´Ù. ½Å°æ¼¼Æ÷¿¡¼­´Â ÀüÇØÁ®¿À´Â ÀÚ±ØÀ» Àü±âÀûÀΠ½ÅÈ£·Î ¹Ù²î¾î º¸³»°Å³ª ¹Þ°Ô µÈ´Ù. ÀÌ·± Àü±âÀûÀΠÇö»óÀº °¢ ½Å°æ¼¼Æ÷³»¿¡ Á¸ÀçÇϴ °¢ ÀÌ¿Âä³Î(ion channel: ionÀ̶õ ³ªÆ®·ý, Ä®·ý µîÀ» ÁöĪÇϴ ¸»µé·Î½á, À̵éÀÌ ¼¼Æ÷¸·¿¡ ÀÇÇØ ³ª´µ¾îÁú ¶§ »ý±â´Â Àü¾ÐÂ÷°¡ Àü±âÀû ÀÚ±ØÀ» ÀÏÀ¸Å°°í À¯ÁöÇϴµ¥ °áÁ¤ÀûÀΠ¿ªÇÒÀ» ÇÑ´Ù)µéÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ÀÌ·ç¾îÁö°Ô µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
  • monocyte lymphocyte ratio
    ´ÜÇÙ±¸¸²ÇÁ±¸ºñÀ²
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸ¹Î°¨¸²ÇÁ±¸Çü°áÁ¤
  • reticular lymphocyte
    ±×¹°¸²ÇÁ±¸, ¸Á»ó¸²ÇÁ±¸
  • sensitized lymphocyte
    ¹Î°¨È­¸²ÇÁ±¸
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¹éÇ÷º´
  • acute lymphocytic leukemia
    ±Þ¼º¸²ÇÁ±¸¹éÇ÷º´
  • acute myelocytic leukemia
    ±Þ¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute promyelocytic leukemia
    ±Þ¼ºÀü°ñ¼ö¼¼Æ÷¹éÇ÷º´, ±Þ¼ºÇ²°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute undifferentiated leukemia
    ±Þ¼º¹ÌºÐÈ­¹éÇ÷º´
  • aleukemic leukemia
    ¹«¹éÇ÷¼º¹éÇ÷º´
  • chloroma leukemia
    ³ì»öÁ¾¹éÇ÷º´
  • chronic lymphoblastic leukemia/small lymphocytic lymphoma
    ¸¸¼º¸²ÇÁ¸ð±¸¹éÇ÷º´/¼Ò¸²ÇÁ±¸¸²ÇÁÁ¾
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸¹éÇ÷º´
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • goblet cell
    ¼úÀܼ¼Æ÷
  • hair cell
    Åм¼Æ÷
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • killer cell
    »ìÇØ¼¼Æ÷
  • Kupffer's cell
    º°Å«Æ÷½Ä¼¼Æ÷, ÄíÆÛ¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • neuroendocrine cell
    ½Å°æ³»ºÐºñ¼¼Æ÷
  • packed red blood cell
    ³óÃàÀûÇ÷±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁ±¸
  • leukocytoid lymphocyte
    ¹éÇ÷±¸¸ð¾ç¸²ÇÁ±¸
  • leukopenic leukemia
    (¢¡aleukemic leukemia) ¹«¹éÇ÷¼º¹éÇ÷º´
  • lymphatic leukemia
    (¢¡lymphoblastic leukemia) ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphoblastic leukemia
    ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • lymphocytic leukemia
    (¢¡lymphoblastic leukemia) ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • megakaryocytic leukemia
    °ÅÇÙ±¸¹éÇ÷º´, °Å´ëÇÙ¼¼Æ÷¹éÇ÷º´
  • monocytic leukemia
    ´ÜÇÙ±¸¹éÇ÷º´
  • monomyelogenous leukemia
    ´ÜÇÙ±¸°ñ¼ö¹éÇ÷º´
  • myeloblastic leukemia
    °ñ¼ö¸ð±¸¹éÇ÷º´
  • myelogenous leukemia
    °ñ¼ö¹éÇ÷º´
  • myelomonocytic leukemia
    °ñ¼ö´ÜÇÙ±¸¹éÇ÷º´
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • promyelocytic leukemia
    Àü°ñ¼ö±¸¹éÇ÷º´, Dz°ñ¼ö¼¼Æ÷¹éÇ÷º´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´(û¡òõá¬øààõ ÛÜúìÜ»)
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷ ¹éÇ÷º´
  • B lymphocyte
    B ¸²ÇÁ±¸
  • B-lymphocyte
    B ¸²ÇÁ±¸.
  • Bare lymphocyte syndrome
    ¹«Ç¥Áö¸²ÇÁ±¸ÁõÈıº
  • T lymphocyte
    T ¸²ÇÁ±¸
  • T-lymphocyte
    T-Àӯı¸
  • anti-lymphocyte globulin
    ¸²ÇÁ±¸ Çױ۷κҸ°
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • leukemia,hairy cell
    ¸ð¹ß»ó ¼¼Æ÷(Ù¾Û¥ßÒ á¬øà)
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¼º ¹éÇ÷º´(?ËôÌ¡ËṴ̂ËÛËÑÌ´ËÓ).
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¹éÇ÷º´
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¼º ¹éÇ÷º´(¡­ë¿ðþá¬øààõÛÜúìÜ»).
  • mast cell leukemia
    ºñ¸¸¼¼Æ÷¼º ¹éÇ÷º´(?ËÛËÑÌ´ËÓ).
  • mast cell leukemia
    ºñ¸¸¼¼Æ÷¼º ¹éÇ÷º´(¡­àõÛÜúìÜ»).
  • mast cell leukemia
    ºñ¸¸¼¼Æ÷¼º ¹éÇ÷º´(¡­àõÛÜúìÜ»)
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷ ¹éÇ÷º´
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´(û¡òõá¬øààõ ÛÜúìÜ»)
  • reticulum cell lymphocytic leukemia
    ¸Á»ó¼¼Æ÷ ¸²ÇÁ±¸¼º ¹éÇ÷º´
  • stem cell leukemia
    °£¼¼Æ÷¼º ¹éÇ÷º´(¡­àõÛÜúìÜ»)
  • t-cell leukemia/lymphoma
    T¼¼Æ÷¹éÇ÷º´/¸²ÇÁÁ¾
  • anti-lymphocyte globulin
    ¸²ÇÁ±¸ Çױ۷κҸ°
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Striated muscle cell
    °¡·Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ⱦ¹®±Ù¼¼Æ÷
  • Sensory epithelial cell
    °¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] °¨°¢»óÇǼ¼Æ÷
  • Cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁú³»ºÐºñ¼¼Æ÷
  • Nodal cell
    °áÀý¼¼Æ÷
    [¿¾ ¿ë¾î] °áÀý¼¼Æ÷
  • Granule cell
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³¼¼Æ÷
  • Granular lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Granulosa lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Myoepithelial cell
    ±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ±Ù»óÇǼ¼Æ÷
  • Myoid cell layer
    ±ÙÀ°¼¶À¯¸ð¼¼Æ÷Ãþ
    [¿¾ ¿ë¾î] ±Ù¼¶À¯¾Æ¼¼Æ÷Ãþ
  • Satellite cell of skeletal muscle
    ±ÙÀ°À§¼º¼¼Æ÷
    [¿¾ ¿ë¾î] ±ÙÀ§¼º¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
  • cell envelope
    ¼¼Æ÷(á¬øà)½Î°³
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • cell fractionation
    ¼¼Æ÷ºÐȹȭ(á¬øàÝÂüñûù)
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
  • cell-free extract
    ¹«¼¼Æ÷ÃßÃâ¹°(Ùíá¬øàõÎõóÚª)
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷
  • daughter cell
    µþ¼¼Æ÷, ³¶¼¼Æ÷
  • dendrite cell
    ³ª¹«°¡Áö¼¼Æ÷, ¼ö»ó¼¼Æ÷
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diffuse large cell lymphoma
    ¹Ì¸¸¼º Å«¼¼Æ÷ÀÓÆÄÁ¾
  • ependymal cell
    ³ú½Ç¸· ¼¼Æ÷, »óÀǼ¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • foam cell
    Æ÷¸» ¼¼Æ÷
  • follicular cell
    ¼ÒÆ÷¼¼Æ÷, ³­Æ÷¼¼Æ÷
  • germ cell
    »ý½Ä¼¼Æ÷, ¹è¼¼Æ÷
  • giant cell
    °Å¼¼Æ÷
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç
  • goblet cell
    ¼úÀܼ¼Æ÷, ¹è³¶¼¼Æ÷
  • granular cell myoblastoma
    °ú¸³¼¼Æ÷±Ù¸ð¼¼Æ÷Á¾
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
FLC family life cycle; fatty liver cell; fetal liver cell; Friend leukemia cell
HTL hamster tumor line; hearing threshold level; high-L-leucine transport; histotechnologist; human T-ce...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BCL1 B cell leukemia
FLC Friend Leukemia Cell
HTLV-I Human T cell leukemia virus I
HTLV-II Human T cell leukemia virus type II
HTLV-I Human T cell leukemia-lymphoma virus type I
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • marrow lymphocyte
    °ñ¼ö ¸²ÇÁ±¸
  • mixed lymphocyte culture
    È¥ÇÕ ¸²ÇÁ±¸ ¹è¾ç
  • monocyte lymphocyte ratio
    ´Ü±¸ ¸²ÇÁ±¸ºñ
  • small lymphocyte
    ÀÛÀº ¸²ÇÁ±¸, ¼Ò¸²ÇÁ±¸
  • thymus-derived lymphocyte
    Èä¼± À¯·¡ Àӯı¸
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´
    ¿ø¹ßÇÏ´Â Á¶Ç÷ Á¶Á÷À̳ª ¹éÇ÷º´ ¼¼Æ÷ÀÇ Á¾·ù¿¡ µû¶ó °ñ¼ö¼º, ¸²ÇÁ¼º, ´Ü±¸¼ºÀ¸·Î ³ª´µ¾îÁö°í Ư¼öÇÑ °ÍÀ¸·Î¼­ Àû¹éÇ÷º´, ÇüÁú ¼¼Æ÷¼º ¹éÇ÷º´, È£»ê±¸¼º ¶Ç´Â È£¿°±â¼º ¹éÇ÷º´ µîÀÌ ÀÖ´Ù.
  • acute lymphoblastic leukemia
    ±Þ¼º ¸²ÇÁ¼º ¹éÇ÷º´
    1. À¯¾Æ ¹× ÀþÀº ¼ºÀο¡ È£¹ßÇÏ´Â Áúȯ. À¯¾Æ ±Þ¼º ¹éÇ÷º´ÀÇ »ó´ç¼ö¸¦ Â÷ÁöÇÑ´Ù. À¯¾Æ¿¡¼­ÀÇ È£¹ß ¿¬·ÉÀº 4¼¼ ÀüÈÄ. ÃÖ±Ù È­Çпä¹ýÀ¸·Î º´¿¡ °É¸° À¯¾ÆÀÇ 90%°¡ ¿ÏÀü Ä¡À¯µÈ´Ù. ¿¹ÈÄ´Â ¿¬·É, ¸é¿ªÇ¥ÇöÇü ±×¸®°í ¼¼Æ÷ À¯ÀüÇÐÀûÀÎ º¯È­¿¡ ÀÇÇØ ¿µÇâÀ» ¹Þ´Â´Ù. 2. ȯÀÚÀÇ 90%°¡ ¹éÇ÷±¸ ¼¼Æ÷¿¡¼­ ÇÙÇü ÀÌ»óÀ» º¸ÀδÙ. ÀϺΠ¼¼Æ÷À¯Àü º¯È­°¡ ¼ºº°, ¿¬·É, ¸é¿ªÇ¥ÇöÇü °°Àº º¯ÀÌ¿ä¼Ò¿Í »ó°ü¾øÀÌ ¿¹ÈÄ¿¡ ´ëÇÑ Á¤º¸¸¦ ÁØ´Ù. 51-60 ¿°»öü »çÀÌÀÇ °í¹è¼ö¼ºÀÌ ¿¹Èİ¡ ÁÁÀº °ÍÀº ÀÌ¹Ì Àß ¾Ë·ÁÁ® ÀÖ´Ù.
  • acute megakaryocytic leukemia
    ±Þ¼º °ÅÇÙ±¸¼º ¹éÇ÷º´
  • acute mixed-lineage leukmia£¨±Þ¼º È¥ÇÕ-Á÷°è¼º ¹éÇ÷º´£©

    acute monocytic leukemia

    ±Þ¼º ´Ü±¸ ¹éÇ÷º´, ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´
    ±Þ¼º ¹éÇ÷º´ÀÇ ÀÏÁ¾À̰í À¯¾à´Ü±¸°¡ ¹éÇ÷º´È­ÇÑ °ÍÀÌ´Ù. °ñ¼ö¿¡¼­ °ú¸³±¸°èÀÇ À¯¾à¼¼Æ÷¿Í ´Ü±¸°èÀÇ À¯¾à¼¼Æ÷°¡ È¥ÀçÇÏ´Â ¼ö°¡ ÀÖ°í ÀÌ °æ¿ì¿¡´Â ±Þ¼º °ñ¼ö´Ü±¸¼º ¹éÇ÷º´À̶ó°í ÇÑ´Ù.
  • acute myelocytic leukemia
    ±Þ¼º °ñ¼ö±¸¼º ¹éÇ÷º´
    ±Þ¼ºÀ¸·Î ¹ßº´ ÁøÇàµÇ´Â °ñ¼ö¼¼Æ÷ ±â¿øÀÇ ¹éÇ÷º´À¸·Î º¸Åë ¿­°ú ÇÔ²² ÀϾ´Ù.
  • acute myelomonoblastic leukemia
    ±Þ¼º °ñ¼ö ´Ü±¸¼º ¹éÇ÷º´
  • aleukemic leukemia
    ¹«¹éÇ÷º´¼º ¹éÇ÷º´
  • chronic granulocytic leukemia
    ¸¸¼º °ú¸³±¸ ¹éÇ÷º´, ¸¸¼º °ú¸³±¸¼º ¹éÇ÷º´
  • chronic myelogenous leukemia
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´Àº Àå³âÃþ¿¡ ÁÖ·Î ¹ß»ýÇÏ¸ç ¹éÇ÷º´ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÑ´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´Àº Á¶Ç÷¸ð¼¼Æ÷ ¼öÁØÀÇ ¾Ï¼º Áõ½ÄÀ¸·Î Áø¼º ÀûÇ÷±¸ Áõ°¡Áõ, Ç÷¼ÒÆÇ Áõ°¡Áõ ¹× °ñ¼ö ¼¶À¯È­Áõ°ú ÇÔ²² °ñ¼ö Áõ½Ä¼º ÁúȯÀ¸·Î ºÐ·ùµÈ´Ù. ¿°»öü 9¹ø°ú 22¹øÀÇ »óÈ£ ÀüÀ§·Î ÀÎÇÑ Çʶóµ¨ÇÇ¾Æ ¿°»öü¿Í ±× »ê¹°ÀÎ bcr-ablÀÌ 95% À̻󿡼­ ¾ç¼ºÀ¸·Î ÀÌ ÁúȯÀÇ º´Àΰú °ü°è°¡ ÀÖ´Â °ÍÀ¸·Î ÀÌÇØµÇ°í ÀÖ´Ù. ÁÖ Áõ»óÀº ºñÀå ºñ´ë·Î ÀÎÇÑ º¹ºÎ ÆØ¸¸ÀÌ Æ¯Â¡ÀûÀÌ¸ç ±×¿Ü °ú´ë»çÁõ µî ÀϹÝÀûÀÎ ¹éÇ÷º´ÀÇ Áõ»óÀÌ ÀÖ´Ù. Áø´ÜÀº Ç÷¾× ¼Ò°ß°ú °ñ¼ö ¼Ò°ß ±×¸®°í ¿°»öü ¹× ºÐÀÚ»ý¹°ÇÐ °Ë»ç¿¡ ÀÇÇÑ bcr-abl ÀÇ Áõ¸í¿¡ ÀÇÇÑ´Ù. ÀÌ ÁúȯÀÇ °æ°ú´Â ¾à 3³âÀÇ ¸¸¼º±â¸¦ Áö³ª°í Àüȯ±â¸¦ °Åó ±Þ¼º ¹éÇ÷º´À¸·Î ÀüȯµÇ¸ç À̶§´Â ÇöÀç ¾Ë·ÁÁø ¾î¶°ÇÑ Ä¡·á ¹æ¹ý¿¡µµ Àß ¹ÝÀÀÇÏÁö ¾Ê´Â´Ù. Ä¡·á´Â °ú°Å¿¡´Â busulfan À̶ó´Â Ç×¾ÏÁ¦°¡, ±Ù·¡¿¡´Â hydrea°¡ ÁÖ·Î »ç¿ëµÇ°í ÀÖÀ¸³ª À̵éÀº ±Þ¼º ¹éÇ÷º´À¸·ÎÀÇ ÀüȯÀ» ¸·Áö ¸øÇÏ¸ç ¹éÇ÷±¸ÀÇ Á¶Àý¿¡¸¸ µµ¿òÀÌ µÉ »Ó Çʶóµ¨ÇÇ¾Æ ¿°»öü°¡ ÀÖ´Â ¾Ï¼¼Æ÷¸¦ Á¦°ÅÇÏÁö´Â ¸øÇÑ´Ù. ±Ù·¡¿¡´Â homoharringtonine µîÀÇ ¾àÁ¦°¡ ¿¬±¸µÇ°í ÀÖ´Ù. 1990³â´ë ¿¡ µîÀåÇÑ ¾ËÆÄÀÎÅÍÆä·Ð ¿ä¹ýÀº ¾à 80%¿¡¼­ Ç÷¾× ¼Ò°ßÀÌ Á¤»óÈ­µÇ°í 20-30%¿¡¼­ Çʶóµ¨ÇÇ¾Æ ¿°»öü°¡ ¼Ò½ÇµÇ´Â µî ¿ì¼öÇÑ ¼ºÀûÀ» º¸À̰í ÀÖÀ¸³ª ±Þ¼º ¹éÇ÷º´À¸·ÎÀÇ ÀüȯÀ» ¸·Áö´Â ¸øÇÏ¸ç ¸¸¼º±â¸¦ ¾à 5³â Á¤µµ·Î ¿¬Àå½ÃŲ´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´À» ¿ÏÄ¡½Ãų ¼ö ÀÖ´Â À¯ÀÏÇÑ Ä¡·á ¹æ¹ýÀº µ¿Á¾ °ñ¼ö À̽ÄÀ¸·Î 55¼¼±îÁö ½ÃÇàÀÌ µÈ´Ù. °ñ¼ö ÀÌ½Ä ÈÄ Àå±â ¹«º´ »ýÁ¸À²Àº ¾à 60-70%ÀÌ¸ç Æ¯È÷ Áø´ÜµÈ ÈÄ 1³â À̳»¿¡ ½ÃÇàÇÏ´Â °ÍÀÌ ±Ç°íµÈ´Ù.
  • chronic myelomonocytic leukemia
    ¸¸¼º °ñ¼ö¼º ´Ü±¸ ¹éÇ÷º´
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
receptors, lymphocyte homing Cell surface glycoproteins on lymphocytes and other leukocytes that mediate adhesion to specialised blood vessels called high endothelial venules. Several different classes of lymphocyte homing receptors have been identified, and they appear to target different surface molecules (addressins) on high endothelial venules in different tissues. The adhesion plays a crucial role in the trafficking of lymphocytes.
(12 Dec 1998)
virgin lymphocyte <haematology, immunology> A lymphocyte that has not and whose precursors have not, encountered the antigenic determinant for which it possesses receptors.
(18 Nov 1997)
CD4 lymphocyte A specific type of lymphocyte, derived from the thymus gland, that plays an important role in cellular immunity. T4 lymphocytes (CD4 cells) are decreased (absolute counts less than 200) in patients with AIDS resulting in compromised immune function.
(27 Sep 1997)
CD4 lymphocyte count A count of the number of CD4-positive lymphocytes in the blood. Determination requires the use of a fluorescence-activated flow cytometer.
(12 Dec 1998)
minor lymphocyte stimulatory antigens Endogenous superantigens responsible for inducing strong proliferative responses in T-cells in mixed lymphocyte reactions (see mixed lymphocyte culture test). They are encoded by mouse mammary tumour viruses that have integrated into the germ line as DNA proviruses (minor lymphocyte stimulatory loci).
(12 Dec 1998)
minor lymphocyte stimulatory loci Genetic loci responsible for the encoding of minor lymphocyte stimulatory antigens. There are at least two unlinked loci (in the mouse) and they appear to be separate from the major histocompatibility complex and minor histocompatibility loci. The mouse mammary tumour virus (see mammary tumour viruses, mouse) has the ability to integrate into these loci. The antigens induce strong T-cell proliferative responses in mixed lymphocyte reactions.
(12 Dec 1998)
mixed lymphocyte culture <investigation> Test to determine whether a patients and donor's white blood cells interact adversely. Often used to determine whether a person would be a suitable bone marrow donor for a particular patient.
(16 Dec 1997)
mixed lymphocyte culture test Measure of histocompatibility at the hl-a locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way mlc test, the lymphocytes from one of the individuals are inactivated (usually by treatment with mitomycin c or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens.
(12 Dec 1998)
mixed lymphocyte reaction <haematology, immunology, investigation> Reaction of mitogenesis produced in T lymphocytes when allogeneic (i.e. Mixed) lymphocytes are brought together, provided they are mismatched in histocompatibility loci. Once used as a test for possible graft compatibility in human grafting. Now known that a negative reaction is a poor predictor of graft acceptance.
(18 Nov 1997)
pre-B lymphocyte An early B-lymphoid type cell that is recognised by immunofluorescence as a u-positive, L-chain-negative bone marrow cell.
(05 Mar 2000)
cytotoxic t-lymphocyte A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene:
See: Ganciclovir.
(09 Oct 1997)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
helper t lymphocyte <haematology, immunology> A type of white blood cell produced by the thymus gland whose presence is necessary for normal levels of antibodies to be produced by B lymphocytes, both in the body (in vivo) and in experimental situations (in vitro).
(09 Oct 1997)
human lymphocyte antigen A system designation for the gene products of at least four linked loci (A, B, C, and D) and a member of subloci on the sixth human chromosome which have been shown to have a strong influence on human allotransplantation, transfusions in refractory patients, and certain disease associations; more than 50 alleles are recognised, most of which are at loci HLA-A and HLA-B; autosomal dominant inheritance.
(05 Mar 2000)
subacute lymphocyte thyroiditis A subacute variant of Hashimoto's thyroiditis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell membrane
    ¼¼Æ÷¸·;¿øÇüÁú¸·;=CELL WALL
  • cell sorter
    ¼¼Æ÷ ºÐº°±â
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cell wall
    ¼¼Æ÷º®
  • cell-mediated immunity
    ¼¼Æ÷(¸Å°³)¼º ¸é¿ª(¼¼Æ÷¸·¿¡ ºÎÂøÇÏ´Â Ç×üÀÇ Á߻꿡 ÀÇÇÑ
  • closed-cell
    µ¶¸³±âÆ÷ÀÇ;¹ÐÆó±âÆ÷ÀÇ(¼ÒÀç´Â ÇÃ¶ó½ºÆ½µî)
  • complementary cell
    º¸Á· ¼¼Æ÷
  • condemned cell (ward)
    »çÇü¼ö °¨¹æ
  • corticopontine cell
    ÇÇÁú±³¼¼Æ÷(´ë³ú ÇÇÁú¿¡ ÀÖÀ¸¸ç ½Ã°¢ ÀÚ±ØÀ» ³ú±³¿¡ º¸³¿)
  • death cell
    »çÇü¼ö °¨¹æ(µ¶¹æ)
  • dry cell
    °ÇÀüÁö
  • egg cell
    ³­¼¼Æ÷;³­ÀÚ
  • fuel cell
    ¿¬·áÀüÁö
  • gangion cell
    ½Å°æÀý ¼¼Æ÷
  • gas cell
    ºñÇ༱ÀÇ °¡½º³¶ÀÇ ÇÑ ±¸È¹;°¡½ºÀüÁö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á